Product Information
ZALEPLON 5 MG CAPSULE is a generic product labeled by Unichem Pharmaceuticals (USA) Inc., priced at $0.1568 per EA under NDC 29300013101. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jun 6, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Unichem Pharmaceuticals (USA) Inc.NDC
29300013101
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ZALEPLONApproval Type
Generic (ANDA)
FDA Application
ANDA078989FDA Approved
6/6/2008
TE Code
AB
On Market Since
5/5/2009
Pharmacological Classes
Price Statistics
The NADAC for ZALEPLON 5 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 37.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1568 per EA |
|---|---|
| All-time high | $0.3049 (Jul 15, 2015) |
| All-time low | $0.1229 (Nov 20, 2024) |
| 52-week high | $0.1638 |
| 52-week low | $0.1444 |
| Median price | $0.1934 |
| Average price | $0.2013 |
| Largest weekly change | +50.5% (Oct 21, 2020) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the zaleplon market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Unichem Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
zaleplon market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
gamma-Aminobutyric Acid A Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZALEPLON 5 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ZALEPLON 5 MG CAPSULE, manufactured by Unichem Pharmaceuticals (USA) Inc., is $0.1568 per EA (NDC 29300013101), effective Sep 30, 2026.
How has the price of ZALEPLON 5 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for ZALEPLON 5 MG CAPSULE has declined 37.1%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ZALEPLON 5 MG CAPSULE?
Since Nov 28, 2013, the NADAC for ZALEPLON 5 MG CAPSULE has ranged from a low of $0.1229 (Nov 20, 2024) to a high of $0.3049 (Jul 15, 2015), with a median of $0.1934 per EA.
Are there cheaper alternatives to ZALEPLON 5 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of ZALEPLON 5 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZALEPLON 5 MG CAPSULE?
ZALEPLON 5 MG CAPSULE (NDC 29300013101) is labeled by Unichem Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.